Last updated: February 17, 2026
Product Overview
NDC 68599-5401 refers to Vericiguat, marketed under the brand name Verquvo. It is approved for the treatment of symptomatic chronic heart failure with reduced ejection fraction (HFrEF). Approved by the FDA in January 2021, Vericiguat functions as a soluble guanylate cyclase stimulator, improving cardiovascular outcomes in heart failure patients.
Market Context
As of 2023, heart failure remains a significant healthcare burden, affecting over 6 million adults in the U.S. The market for heart failure medications is expansive, driven by aging populations and ongoing clinical needs. Vericiguat positioned as an adjunct therapy targeting a subset of HFrEF patients who have elevated risk despite standard treatments.
Market Penetration and Competition
The drug competes primarily with established heart failure treatments such as:
- ACE inhibitors/ARBs (e.g., enalapril, losartan)
- Beta-blockers (e.g., carvedilol, bisoprolol)
- ARNI (sacubitril/valsartan)
- SGLT2 inhibitors (empagliflozin, dapagliflozin)
Vericiguat's incremental benefit over standard therapy influences its adoption. Its position as a third-line agent limits market share initially but projected growth depends on clinical adoption rates and indication expansion.
Market Size and Revenue Forecasts
Based on sales data from 2022–2023, Vericiguat generated approximately $300 million in U.S. sales. The global market for HFrEF therapies is projected to grow from $8 billion in 2022 to $12 billion by 2027** ([1], [2]).
Assuming Vericiguat captures 5-10% of the heart failure drug market in the next five years, the revenue potential could reach:
| Year |
Estimated U.S. Revenue |
Global Market Share |
Global Revenue Projection |
| 2024 |
$350M |
6% |
$720M |
| 2025 |
$400M |
8% |
$960M |
| 2026 |
$500M |
10% |
$1.2B |
Pricing Analysis and Projections
Current Pricing (as of 2023):
The average wholesale price (AWP) for Verquvo is approximately $650 per month. The typical dosage regimen involves 2.5 mg daily, titrated upward based on patient response.
Annual Cost Estimate:
At $650/month, annual cost per patient approximates $7,800.
Price Trends and Influencing Factors:
- Market Competition: Entry of generics or biosimilars in related categories could pressure pricing.
- Reimbursement Policies: Payer negotiations and inclusion in formularies significantly influence net prices.
- Clinical Data: Positive outcomes could support price premiums; negative or competitive data could lead to discounts.
Projected Price Trajectory:
| Year |
Expected Monthly Price |
Rationale |
| 2024 |
$650 |
Stable, considering existing contracts and minimal biosimilar presence |
| 2025 |
$625 |
Slight decline due to increased market competition and negotiations |
| 2026 |
$600 |
Possible further reduction driven by biosimilar entry or generic options in the future |
Regulatory and Policy Impact:
- Medicare and private insurers' formulary decisions will influence access and net pricing.
- Price negotiation under the Inflation Reduction Act (IRA) could impact reimbursement levels in 2024 and beyond.
Conclusion:
Vericiguat (NDC 68599-5401) offers a niche but growing opportunity within the heart failure market. Its pricing remains relatively stable with modest downward pressure expected as market dynamics evolve. Its revenue growth depends on clinical adoption, guideline inclusion, and competitive landscape shifts.
Key Takeaways
- Vericiguat targets a specific segment within HFrEF, with moderate market penetration expected.
- Current U.S. wholesale price is around $650/month, with potential gradual decreases.
- Revenue projections suggest a rise to roughly $1.2 billion globally by 2026 if market shares increase.
- Competitive pressures and policy changes will significantly influence future pricing.
- Its success hinges on clinical efficacy, payer acceptance, and market adoption.
FAQs
1. What is the primary therapy class of NDC 68599-5401?
It is a soluble guanylate cyclase stimulator used to treat heart failure with reduced ejection fraction.
2. How does Vericiguat compare to other heart failure treatments?
It offers benefits for patients at high risk despite standard therapy but is considered a third-line agent, with a niche role.
3. What factors could influence the drug's price in the future?
Market competition, biosimilar entry, payer negotiations, and new clinical data.
4. How significant is the potential global market for Vericiguat?
The global market for heart failure therapies is projected to reach $12 billion in 2027, with Vericiguat potentially capturing up to 10%.
5. How does insurance coverage impact Vericiguat's pricing?
Reimbursement negotiations and formulary inclusion directly influence net prices and patient access.
References
[1] GlobalData. Heart Failure Therapeutics Market Forecast, 2022-2027.
[2] IQVIA. United States Prescription Drug Market Data, 2022-2023.
[3] FDA. Verquvo (Vericiguat) Approval Announcement, January 2021.
